US Stock MarketDetailed Quotes

SGMO Sangamo Therapeutics

Watchlist
  • 2.470
  • +0.160+6.93%
Close Dec 20 16:00 ET
  • 2.480
  • +0.010+0.40%
Post 20:01 ET
515.36MMarket Cap-3.48P/E (TTM)

Sangamo Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
425.77%49.41M
-94.79%356K
-99.70%481K
58.34%176.23M
-92.50%2.04M
-64.48%9.4M
-76.73%6.84M
459.52%157.96M
0.54%111.3M
-2.70%27.23M
Operating revenue
425.77%49.41M
-94.79%356K
-99.70%481K
58.34%176.23M
-92.50%2.04M
-64.48%9.4M
-76.73%6.84M
459.52%157.96M
0.54%111.3M
-2.70%27.23M
Cost of revenue
Gross profit
Operating expense
-45.38%38.78M
-54.13%36.27M
-41.42%47.66M
-5.55%295.22M
-22.77%63.81M
-12.72%71.01M
5.26%79.06M
10.70%81.35M
6.31%312.58M
21.71%82.62M
Selling and administrative expenses
-20.61%11.05M
-24.78%12.05M
-35.12%11.77M
-2.42%61.17M
-20.34%13.1M
-14.29%13.92M
6.10%16.01M
21.65%18.14M
-0.85%62.68M
2.23%16.44M
-General and administrative expense
-20.61%11.05M
-24.78%12.05M
-35.12%11.77M
-2.42%61.17M
-20.34%13.1M
-14.29%13.92M
6.10%16.01M
21.65%18.14M
-0.85%62.68M
2.23%16.44M
Research and development costs
-51.42%27.73M
-61.58%24.22M
-43.22%35.89M
-6.34%234.06M
-23.38%50.71M
-12.33%57.09M
5.04%63.05M
7.91%63.22M
8.27%249.9M
27.76%66.18M
Operating profit
117.26%10.63M
50.28%-35.91M
-161.58%-47.18M
40.88%-118.99M
-11.50%-61.76M
-12.23%-61.61M
-57.92%-72.23M
269.25%76.61M
-9.79%-201.28M
-38.83%-55.39M
Net non-operating interest income expense
-96.33%129K
-63.24%1.03M
-23.02%2.54M
17.71%11.1M
-59.43%1.49M
98.70%3.52M
6.02%2.8M
145.38%3.29M
76.43%9.43M
57.45%3.68M
Non-operating interest income
-96.33%129K
----
----
17.71%11.1M
-59.43%1.49M
98.70%3.52M
----
----
76.43%9.43M
--3.68M
Total other finance cost
----
63.24%-1.03M
23.02%-2.54M
----
----
----
-6.02%-2.8M
-145.38%-3.29M
----
----
Other net income (expense)
97.72%-1.17M
92.57%-4.35M
-155.01M
-296K
-44.8M
-51.35M
-58.57M
Special income (charges)
--0
97.72%-1.17M
92.57%-4.35M
---155.01M
---296K
---44.8M
---51.35M
---58.57M
--0
--0
-Less:Impairment of capital assets
--0
-97.72%1.17M
-92.57%4.35M
--155.01M
--296K
--44.8M
--51.35M
--58.57M
--0
--0
Income before tax
110.46%10.76M
70.15%-36.05M
-329.71%-48.99M
-37.04%-262.9M
-17.12%-60.57M
-93.68%-102.89M
-180.27%-120.77M
148.56%21.33M
-7.79%-191.85M
-37.67%-51.71M
Income tax
-93.07%88K
101.18%74K
-49.48%98K
-1,282.28%-5.07M
-205.02%-272K
4,133.33%1.27M
-7,739.02%-6.26M
234.48%194K
40.20%429K
486.57%259K
Net income
110.25%10.67M
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.84%-192.28M
-38.61%-51.97M
Net income continuous Operations
110.25%10.67M
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.84%-192.28M
-38.61%-51.97M
Minority interest income
0
0
Net income attributable to the parent company
110.25%10.67M
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.85%-192.28M
-38.61%-51.97M
Preferred stock dividends
Other preferred stock dividends
1.29M
0
Net income attributable to common stockholders
109.01%9.39M
68.45%-36.13M
-332.29%-49.09M
-34.09%-257.83M
-16.01%-60.3M
-95.96%-104.16M
-165.23%-114.51M
148.05%21.13M
-7.85%-192.28M
-38.61%-51.97M
Basic earnings per share
108.47%0.05
72.73%-0.18
-307.69%-0.27
-18.40%-1.48
-6.25%-0.34
-73.53%-0.59
-127.59%-0.66
143.33%0.13
-1.63%-1.25
-23.08%-0.32
Diluted earnings per share
106.78%0.04
72.73%-0.18
-325.00%-0.27
-18.40%-1.48
-6.25%-0.34
-73.53%-0.59
-127.59%-0.66
140.00%0.12
-1.63%-1.25
-23.08%-0.32
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
--
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 425.77%49.41M-94.79%356K-99.70%481K58.34%176.23M-92.50%2.04M-64.48%9.4M-76.73%6.84M459.52%157.96M0.54%111.3M-2.70%27.23M
Operating revenue 425.77%49.41M-94.79%356K-99.70%481K58.34%176.23M-92.50%2.04M-64.48%9.4M-76.73%6.84M459.52%157.96M0.54%111.3M-2.70%27.23M
Cost of revenue
Gross profit
Operating expense -45.38%38.78M-54.13%36.27M-41.42%47.66M-5.55%295.22M-22.77%63.81M-12.72%71.01M5.26%79.06M10.70%81.35M6.31%312.58M21.71%82.62M
Selling and administrative expenses -20.61%11.05M-24.78%12.05M-35.12%11.77M-2.42%61.17M-20.34%13.1M-14.29%13.92M6.10%16.01M21.65%18.14M-0.85%62.68M2.23%16.44M
-General and administrative expense -20.61%11.05M-24.78%12.05M-35.12%11.77M-2.42%61.17M-20.34%13.1M-14.29%13.92M6.10%16.01M21.65%18.14M-0.85%62.68M2.23%16.44M
Research and development costs -51.42%27.73M-61.58%24.22M-43.22%35.89M-6.34%234.06M-23.38%50.71M-12.33%57.09M5.04%63.05M7.91%63.22M8.27%249.9M27.76%66.18M
Operating profit 117.26%10.63M50.28%-35.91M-161.58%-47.18M40.88%-118.99M-11.50%-61.76M-12.23%-61.61M-57.92%-72.23M269.25%76.61M-9.79%-201.28M-38.83%-55.39M
Net non-operating interest income expense -96.33%129K-63.24%1.03M-23.02%2.54M17.71%11.1M-59.43%1.49M98.70%3.52M6.02%2.8M145.38%3.29M76.43%9.43M57.45%3.68M
Non-operating interest income -96.33%129K--------17.71%11.1M-59.43%1.49M98.70%3.52M--------76.43%9.43M--3.68M
Total other finance cost ----63.24%-1.03M23.02%-2.54M-------------6.02%-2.8M-145.38%-3.29M--------
Other net income (expense) 97.72%-1.17M92.57%-4.35M-155.01M-296K-44.8M-51.35M-58.57M
Special income (charges) --097.72%-1.17M92.57%-4.35M---155.01M---296K---44.8M---51.35M---58.57M--0--0
-Less:Impairment of capital assets --0-97.72%1.17M-92.57%4.35M--155.01M--296K--44.8M--51.35M--58.57M--0--0
Income before tax 110.46%10.76M70.15%-36.05M-329.71%-48.99M-37.04%-262.9M-17.12%-60.57M-93.68%-102.89M-180.27%-120.77M148.56%21.33M-7.79%-191.85M-37.67%-51.71M
Income tax -93.07%88K101.18%74K-49.48%98K-1,282.28%-5.07M-205.02%-272K4,133.33%1.27M-7,739.02%-6.26M234.48%194K40.20%429K486.57%259K
Net income 110.25%10.67M68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.84%-192.28M-38.61%-51.97M
Net income continuous Operations 110.25%10.67M68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.84%-192.28M-38.61%-51.97M
Minority interest income 00
Net income attributable to the parent company 110.25%10.67M68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.85%-192.28M-38.61%-51.97M
Preferred stock dividends
Other preferred stock dividends 1.29M0
Net income attributable to common stockholders 109.01%9.39M68.45%-36.13M-332.29%-49.09M-34.09%-257.83M-16.01%-60.3M-95.96%-104.16M-165.23%-114.51M148.05%21.13M-7.85%-192.28M-38.61%-51.97M
Basic earnings per share 108.47%0.0572.73%-0.18-307.69%-0.27-18.40%-1.48-6.25%-0.34-73.53%-0.59-127.59%-0.66143.33%0.13-1.63%-1.25-23.08%-0.32
Diluted earnings per share 106.78%0.0472.73%-0.18-325.00%-0.27-18.40%-1.48-6.25%-0.34-73.53%-0.59-127.59%-0.66140.00%0.12-1.63%-1.25-23.08%-0.32
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----------------Unqualified Opinion--
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme Gene Editing
Gene Editing
Intraday+0.52%